BioInvent International Aktiebolag financials
BioInvent International Aktiebolag
549300E7QRHEF2IJUY10 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 44.7M | SEK 71.5M |
| Operating profit (EBIT) | -SEK 471.1M | -SEK 369.9M |
| Net finance income / (cost) | SEK 41.8M | SEK 39.8M |
| Finance costs | SEK 649.0K | SEK 1.5M |
| Profit before tax | -SEK 429.2M | -SEK 330.1M |
| Income tax expense | SEK 135.0K | SEK 204.0K |
| Profit for the year | -SEK 429.4M | -SEK 330.3M |
| Total comprehensive income | -SEK 429.4M | -SEK 330.3M |
| Per share | ||
| Basic EPS | SEK -6.53 | SEK -5.02 |
| Diluted EPS | SEK -6.53 | SEK -5.02 |
| Free cash flow / share | SEK -5.94 | SEK -5.40 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 380.5M | -SEK 341.7M |
| Net cash from investing activities | SEK 564.3M | SEK 59.7M |
| Purchase of PP&E (capex) | SEK 10.0M | SEK 13.3M |
| Net cash from financing activities | -SEK 8.5M | SEK 23.1M |
| Lease liability payments | SEK 8.5M | SEK 7.8M |
| Balance sheet | ||
| Total assets | SEK 989.2M | SEK 1.40B |
| Non-current assets | SEK 46.0M | SEK 266.9M |
| Right-of-use assets | SEK 17.7M | SEK 23.2M |
| Current assets | SEK 943.2M | SEK 1.13B |
| Inventories | SEK 11.0M | SEK 11.8M |
| Trade & other receivables | SEK 8.3M | SEK 11.9M |
| Cash & equivalents | SEK 434.8M | SEK 259.5M |
| Total equity | SEK 885.8M | SEK 1.31B |
| — attributable to owners | SEK 885.8M | SEK 1.31B |
| Non-current liabilities | SEK 8.2M | SEK 14.5M |
| Lease liabilities (non-current) | SEK 8.2M | SEK 14.5M |
| Current liabilities | SEK 95.2M | SEK 75.9M |
| Lease liabilities (current) | SEK 9.2M | SEK 8.7M |
| Derived metrics | ||
| Free cash flow | -SEK 390.5M | -SEK 355.0M |
| Operating margin | -1054.2% | -517.7% |
| Net margin | -960.9% | -462.2% |
| Return on equity | -48.5% | -25.2% |
| Cash conversion ratio | 0.89× | 1.03× |
| Capex coverage | -37.92× | -25.68× |
| Other reported items | ||
| Additional Paidin Capital | SEK 3.76B | SEK 3.76B |
| Adjustments For Decrease Increase In Inventories | SEK 877.0K | -SEK 338.0K |
| Adjustments For Decrease Increase In Trade and Other Receivables | -SEK 12.4M | SEK 2.4M |
| Adjustments For Depreciation and Amortisation Expense | SEK 19.3M | SEK 16.8M |
| Adjustments For Increase Decrease In Trade and Other Payables | SEK 19.1M | -SEK 12.2M |
| Cash | SEK 75.6M | SEK 52.5M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 388.0M | -SEK 331.5M |
| Comprehensive Income Attributable To Owners of Parent | -SEK 429.4M | -SEK 330.3M |
| Current Accruals and Current Deferred Income Including Current Contract Liabilities | SEK 30.2M | SEK 32.2M |
| Current Financial Assets | SEK 432.3M | SEK 809.2M |
| Current Prepayments and Current Accrued Income Other Than Current Contract Assets | SEK 39.9M | SEK 20.1M |
| Equity and Liabilities | SEK 989.2M | SEK 1.40B |
| Expense By Nature | SEK 515.7M | SEK 441.4M |
| Finance Income | SEK 42.5M | SEK 41.4M |
| Income Taxes Paid Refund Classified As Operating Activities | SEK 114.0K | SEK 90.0K |
| Increase Decrease In Cash and Cash Equivalents | SEK 175.4M | -SEK 258.9M |
| Increase Decrease In Working Capital | -SEK 7.6M | SEK 10.1M |
| Increase Decrease Through Sharebased Payment Transactions | SEK 5.5M | SEK 3.0M |
| Intangible Assets Other Than Goodwill | SEK 0 | SEK 0 |
| Interest Paid Classified As Operating Activities | SEK 555.0K | SEK 638.0K |
| Interest Received Classified As Operating Activities | SEK 58.9M | SEK 19.4M |
| Issue of Equity | — | SEK 31.0M |
| Issued Capital | SEK 13.2M | SEK 13.2M |
| Miscellaneous Other Operating Expense | SEK 830.0K | SEK 742.0K |
| Noncurrent Financial Assets | SEK 0 | SEK 214.3M |
| Office Equipment | SEK 27.7M | SEK 29.1M |
| Other Adjustments For Noncash Items | SEK 5.5M | SEK 3.0M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | SEK 0 | SEK 0 |
| Other Current Payables | SEK 6.7M | SEK 5.8M |
| Other Operating Income Expense | SEK 1.1M | SEK 1.4M |
| Other Receivables | SEK 16.9M | SEK 20.7M |
| Proceeds From Issuing Shares | SEK 0 | SEK 31.0M |
| Purchase of Financial Instruments Classified As Investing Activities | -SEK 574.4M | -SEK 73.0M |
| Research and Development Expense | SEK 457.7M | SEK 390.4M |
| Reserve of Gains and Losses On Financial Assets Measured At Fair Value Through Other Comprehensive Income | SEK 1.0K | SEK 1.0K |
| Retained Earnings | -SEK 2.89B | -SEK 2.46B |
| Selling General and Administrative Expense | SEK 58.3M | SEK 51.6M |
| Shortterm Investments Classified As Cash Equivalents | SEK 359.3M | SEK 207.1M |
| Trade and Other Current Payables To Trade Suppliers | SEK 49.1M | SEK 29.2M |
Every line item above is a fact tagged in BioInvent International Aktiebolag's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.